La catena delle opzioni mostra i dati chiave delle opzioni azionarie di Janux Therapeutics a vari prezzi di esercizio e date di scadenza. I trader utilizzano queste informazioni per analizzare potenziali operazioni e valutare il sentiment del mercato per Janux Therapeutics..

Janux Therapeutics (NASDAQ:JANX) Azioni, Catena delle Opzioni

Janux Therapeutics

Janux Therapeutics Inc is a clinical-stage biopharmaceutical company developing next-generation therapeutics based on proprietary tumor activated T Cell Engager platform technology to treat patients suffering from cancer.

Janux Therapeutics Inc

Protagonist Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PTGX#NASDAQ">PTGX</a>) reported quarterly losses of $(0.54) per share which beat the analyst consensus estimate of $(0.63) by 14.29 percent. This is a 6.9 percent increase over losses of $(0.58) per share from the same period last year. The company reported quarterly sales of $4.67 million which beat the analyst consensus estimate of $2.07 million by 125.74 percent.

Earnings

Earnings Beats

News

PTGX

Protagonist Therapeutics Q3 EPS $(0.54) Beats $(0.63) Estimate, Sales $4.67M Beat $2.07M Estimate

Backblaze (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BLZE#NASDAQ">BLZE</a>) reported quarterly losses of $(0.10) per share which beat the analyst consensus estimate of $(0.24) by 58.33 percent. This is a 52.38 percent increase over losses of $(0.21) per share from the same period last year. The company reported quarterly sales of $32.59 million which beat the analyst consensus estimate of $32.44 million by 0.46 percent. This is a 28.82 percent increase over sales of $25.30 million the same period last year.

BLZE

Backblaze Q3 Adj $(0.10) Beats $(0.24) Estimate, Sales $32.59M Beat $32.44M Estimate

WIIM

WBTN

Webtoon entertainment shares are trading higher after the company reported a year-over-year increase in Q3 adjusted EPS results and better-than-expected Q3 revenue results.

Portman Ridge Finance (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PTMN#NASDAQ">PTMN</a>) reported quarterly earnings of $0.63 per share which missed the analyst consensus estimate of $0.68 by 7.35 percent. The company reported quarterly sales of $15.177 million which missed the analyst consensus estimate of $16.256 million by 6.64 percent. This is a 18.29 percent decrease over sales of $18.574 million the same period last year.

Earnings Misses

PTMN

Portman Ridge Finance Q3 2024 GAAP EPS $0.63 Misses $0.68 Estimate, Sales $15.177M Miss $16.256M Estimate

Silvercorp Metals (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/SVM#AMEX">SVM</a>) reported quarterly earnings of $0.07 per share which missed the analyst consensus estimate of $0.08 by 12.5 percent. The company reported quarterly sales of $68.00 million which beat the analyst consensus estimate of $65.04 million by 4.55 percent. This is a 25.94 percent increase over sales of $53.99 million the same period last year.

Silvercorp Metals Q2 2025 Adj EPS $0.07 Misses $0.08 Estimate, Sales $68.00M Beat $65.04M Estimate

Guidance

CNHI Says The Company's Forecast Of Continued Weak Industry Retail Demand In Both The Agriculture And Construction Equipment Markets, Coupled With Elevated Dealer Inventories Is Requiring Lower Production Levels; Sees 2024 Adj. EPS $1.05-$1.15 (Prior $1.30-$1.40)

Funko (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FNKO#NASDAQ">FNKO</a>) lowers FY2024 sales outlook from $1.05 billion-1.10 billion to $1.04 billion-1.05 billion.

FNKO

Funko Lowers FY2024 Sales Guidance from $1.05B-1.10B to $1.04B-1.05B  VS Est.1.07B

Wheaton Precious Metals Expects Estimated Attributable Production In 2024 To Be 325K-370K Ounces Of Gold; 18.5M-20.5M Ounces Of Silver.

Brilliant Earth Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BRLT#NASDAQ">BRLT</a>) reported quarterly earnings of $0.02 per share which beat the analyst consensus estimate of $0.00 by Infinity percent. The company reported quarterly sales of $99.873 million which missed the analyst consensus estimate of $100.250 million by 0.38 percent. This is a 12.51 percent decrease over sales of $114.154 million the same period last year.

BRLT

Brilliant Earth Group Q3 2024 Adj. EPS $0.02 Beats $0.00 Estimate, Sales $99.873M Miss $100.250M Estimate

AvePoint (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AVPT#NASDAQ">AVPT</a>) raises FY2024 sales outlook from $320.20 million-324.20 million to $327.80 million-329.80 million.

AVPT

AvePoint Raises FY2024 Sales Guidance from $320.20M-324.20M to $327.80M-329.80M

Buybacks

EOG Resources Approves $5B Increase In Share Repurchase Authorization

AvePoint (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AVPT#NASDAQ">AVPT</a>) sees Q4 sales of $86.500 million-88.500 million vs $86.80 million estimate.

AvePoint Sees Q4 Sales $86.500M-88.500M vs $86.80M Est

Pebblebrook Hotel (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PEB#NYSE">PEB</a>) lowers FY2024 FFO guidance from $1.59-1.67 to $1.57-1.60 vs $1.61 analyst estimate..

Pebblebrook Hotel Lowers FY2024 FFO Guidance from $1.59-1.67 to $1.57-1.60 vs $1.61 Est

Heritage Glb (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HGBL#NASDAQ">HGBL</a>) reported quarterly earnings of $0.03 per share which missed the analyst consensus estimate of $0.06 by 50 percent. This is a 40 percent decrease over earnings of $0.05 per share from the same period last year. The company reported quarterly sales of $10.41 million which missed the analyst consensus estimate of $13.37 million by 22.14 percent. This is a 33.06 percent decrease over sales of $15.55 million the same period last year.

HGBL

Heritage Glb Q3 EPS $0.03 Misses $0.06 Estimate, Sales $10.41M Miss $13.37M Estimate

Pebblebrook Hotel (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PEB#NYSE">PEB</a>) is looking for Q4 FFO of $0.08-0.11 vs $0.19 analyst estimate..

Pebblebrook Hotel Sees Q4 FFO $0.08-0.11 vs $0.19 Est

Axonics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AXNX#NASDAQ">AXNX</a>) reported quarterly sales of $116.20 million which beat the analyst consensus estimate of $113.50 million by 2.38 percent. This is a 24.81 percent increase over sales of $93.10 million the same period last year.

AXNX

Axonics Q3 Sales $116.20M Beat $113.50M Estimate; EPS $0.00 Vs $0.08 YoY

CNH Industrial Q3 EPS $0.24 Misses $0.28 Estimate, Sales $4.65B Beat $4.61B Estimate

Funko (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FNKO#NASDAQ">FNKO</a>) is looking for Q4 Adj EPS of $(0.05)-0.02 vs $0.02 analyst estimate. seessales of $280.000 million-294.000 million vs $316.37 million estimate.

Funko Sees Q4 Adj EPS $(0.05)-0.02 vs $0.02 Est; Sees Sales $280.000M-294.000M vs $316.37M Est

Alpha Teknova (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TKNO#NASDAQ">TKNO</a>) reported quarterly losses of $(0.15) per share which missed the analyst consensus estimate of $(0.10) by 50 percent. This is a 55.88 percent increase over losses of $(0.34) per share from the same period last year. The company reported quarterly sales of $9.576 million which beat the analyst consensus estimate of $9.190 million by 4.20 percent. This is a 17.22 percent increase over sales of $8.169 million the same period last year.

TKNO

Alpha Teknova Q3 2024 GAAP EPS $(0.15) Misses $(0.10) Estimate, Sales $9.576M Beat $9.190M Estimate

Expands Lantronix&#39;s IoT Wireless Connect Portfolio With Cutting-Edge 5G Technology
<ul>
<li>Strengthens Competitive Offering, Adds New Blue-Chip Customers</li>
</ul>
IRVINE, Calif., Nov. 07, 2024 (GLOBE NEWSWIRE) -- <a href="https://www.globenewswire.com/Tracker?data=hB3l4_jGgHsp-mU6f7YA39RB4tNFMkAA8OovErBPAK-V5ySYJi0YOjUuTG9Znzyv8NTl9eDh7MpcoWwIPs76bHVRycPMRk5eNIZ8Rnh3hyfE9uaOgBHaqhLzAkbq4hQo0VCiKCDozG3FJNNIHakKmUGncG6nXL9x4bRp7O1SQQm0gpDf9bQe79ZAY9SDAgzQ">Lantronix Inc.</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LTRX#NASDAQ">LTRX</a>), a global leader in IoT compute and connectivity IoT solutions, today announced that it has signed a definitive agreement to acquire from NetComm Wireless Pty Ltd (&quot;NetComm&quot;), a subsidiary of DZS, Inc., all of the assets of its enterprise Internet of Things (IoT) business for $6.5 million in cash together with assumptions of certain liabilities. The acquisition complements Lantronix&#39;s focus on the Enterprise and Smart City vertical markets and expands its next-generation 5G capabilities.

Asset Sales

DZSI

LTRX

Lantronix Accelerates IoT Leadership With Strategic Acquisition Of DZS's NetComm Enterprise IoT Portfolio For $6.5M In Cash Together With Assumptions Of Certain Liabilities

Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on BioNTech SE (BNTX – Research Report), Lyell Immuno...

Analysts Offer Insights on Healthcare Companies: BioNTech SE (BNTX), Lyell Immunopharma (LYEL) and Janux Therapeutics Inc (JANX)

Janux Therapeutics: Buoyed By Buyout Speculation

Janux initiated at Stifel with Buy on upcoming data update

The most talked about and market moving research calls around Wall Street are now in one place. Here are today's research calls that investors need...

Verizon downgraded, Canadian Pacific upgraded: Wall Street's top analyst calls

UBS launches SMID cap biotechs with cancer, autoimmunity in focus

JonesTrading analyst Soumit Roy has maintained their bullish stance on JANX stock, giving a Buy rating on October 24. Soumit Roy has given his Buy ...

Promising Outlook for Janux Therapeutics Ahead of Key Phase 1 Data Release

TD Cowen analyst Marc Frahm has maintained their bullish stance on JANX stock, giving a Buy rating on October 31. Marc Frahm's rating is based on p...

Promising Phase I Trial Results and Tolerability Boost Buy Rating for Janux Therapeutics' JANX007 in mCRPC Treatment

Janux Therapeutics GAAP EPS of -$0.51 misses by $0.13, revenue of $0.44M misses by $1.23M

In a report released today, Justin Zelin from BTIG maintained a Buy rating on Janux Therapeutics Inc (JANX – Research Report), with a price target ...

Janux Therapeutics Inc (JANX) Receives a Buy from BTIG

Scotiabank analyst George Farmer maintained a Hold rating on Janux Therapeutics Inc (JANX – Research Report) today and set a price target of $42.00...

Comments

Janux Therapeutics

Janux Therapeutics (JANX) Opzioni

Janux Therapeutics (NASDAQ:JANX) Azioni, Catena delle Opzioni

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO